Literature DB >> 3378160

Effects of aminopeptidase inhibition on the half-lives of [125I]angiotensins in the cerebroventricles of the rat.

A L Dewey1, J W Wright, J M Hanesworth, J W Harding.   

Abstract

Anesthetized Sprague-Dawley rats fitted with intracerebroventricular (i.c.v.) cannulas were infused with one of the aminopeptidase inhibitors, amastatin or bestatin, over a 5-min period. After infusion, 1-2 X 10(6) cpm of [125I]angiotensin II ([125I]AII) or [125I]angiotensin III ([125I]AIII) was injected through the same cannula. The rats were subsequently killed 60 s later by focused microwave irradiation which instantaneously terminated further [125I]angiotensin metabolism. HPLC analysis of the extracted [125I]angiotensin and metabolic products allowed for the calculation of t1/2s of disappearance for the parent peptides. Both inhibitors effectively lengthened the half-lives of [125I]AII and [125I]AIII. Bestatin, which is considered a selective aminopeptidase B blocker, had a more pronounced effect on [125I]AIII metabolism, while amastatin, a selective aminopeptidase A inhibitor, was better at slowing [125I]AII degradation. The results indicate that amastatin and bestatin are very effective blockers of the cerebroventricular metabolism of angiotensins but are only marginally selective with regard to AII and AIII.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3378160     DOI: 10.1016/0006-8993(88)91279-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

1.  Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.

Authors:  S Zini; M C Fournie-Zaluski; E Chauvel; B P Roques; P Corvol; C Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

2.  Central angiotensin II has catabolic action at white and brown adipose tissue.

Authors:  Annette D de Kloet; Eric G Krause; Karen A Scott; Michelle T Foster; James P Herman; Randall R Sakai; Randy J Seeley; Stephen C Woods
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-08-23       Impact factor: 4.310

Review 3.  Aminopeptidase A inhibitors as centrally acting antihypertensive agents.

Authors:  Laurence Bodineau; Alain Frugière; Yannick Marc; Cédric Claperon; Catherine Llorens-Cortes
Journal:  Heart Fail Rev       Date:  2008-01-03       Impact factor: 4.214

4.  Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.

Authors:  Alene T McCoy; Caroline C Benoist; John W Wright; Leen H Kawas; Jyote M Bule-Ghogare; Mingyan Zhu; Suzanne M Appleyard; Gary A Wayman; Joseph W Harding
Journal:  J Pharmacol Exp Ther       Date:  2012-10-10       Impact factor: 4.030

Review 5.  Aminopeptidase N in arterial hypertension.

Authors:  Robert S Danziger
Journal:  Heart Fail Rev       Date:  2007-11-16       Impact factor: 4.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.